BREAST CANCER CONNECT

💭 Have you ever thought about the daily challenges faced by those battling metastatic breast cancer? Or wondered how best to support a loved one after their diagnosis? Stay tuned! We’re about to share a powerful video series featuring three inspiring women—Sue, Chelsey, and Tiffany—who are navigating their journeys with metastatic breast cancer. Whether you're a person living with breast cancer, a family member, or an HCP, this series is for you. Across 4 videos, these incredible women will answer some of the most insightful questions: 1. What do you wish people understood about your experience? 2. How can families best support their loved ones through this journey? 3. What do you wish healthcare professionals knew or did differently? 4. Looking back, what advice would you give yourself at diagnosis? Join the conversation and remember: the breast cancer journey doesn’t end the 31st of October! #BreastCancerAwarnessMonth

🎗️ October is Breast Cancer Awareness Month! Did you know? 🌸 1 in 8 women will be diagnosed with breast cancer in their lifetime. 🌸 Early detection boosts survival rates up to 99%. 🌸 Men are affected too—1 in 100 breast cancer diagnoses are male. Medical education plays a crucial role in translating science into clinical practice, improving early detection, treatment, and patient outcomes. By staying informed, healthcare professionals can turn breakthroughs into life-saving care. Together, we can make a difference! 💪 👉Check out our website for invaluable resources on #BreastCancer: https://ow.ly/jh4e50TznE6 #MedEd

❗ Breast cancer update from #ESMO24 ❗ Prof. François-Clément Bidard shares his views on new breast cancer data from ESMO 2024, and the potential impact on clinical practice. Watch his video update below 📺 Prof. François-Clément Bidard references the following trials: 👉 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study. Schmid P, et al. (Abstract LBA4) 👉 Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINYBreast-12 primary results. Lin N, et al. (Abstract LBA18) 👉 Adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with HR+/HER2− early breast cancer: 4-year outcomes from the NATALEE trial. Fasching P, et al. (Abstract LBA13) Get more updates from ESMO across multiple tumour types in this video series from renowned medical experts: https://lnkd.in/ew4yMSZd #MedicalEducation #oncology

🚨FDA approves ribociclib with an aromatase inhibitor for adjuvant treatment of patients with stage II or III HR+/HER2- early breast cancer at high risk of recurrence. In the NATALEE trial with over 5,000 patients, adding ribociclib showed a 5% iDFS benefit at 4 years. This approval places ribociclib alongside abemaciclib as a key CDK4/6 inhibitor in the adjuvant setting, providing more options for high-risk patients. What are your thoughts on this recent approval? Find more information here ➡️ https://lnkd.in/d6-Bf8jS

#ESMO2024 I LBA18 🔥📊DESTINYBreast-12 primary results for HER2+ mBC with brain metastases: 🔹 12-month PFS: 61.6% in BM cohort 🔹 12-month CNS PFS: 58.9% 🔹 CNS ORR: 79.2% (stable BM), 62.3% (active BM) 🔹 ILD/pneumonitis: 16.0% in BM cohort, 12.9% in non-BM cohort T-DXd shows strong intracranial activity with manageable side effects. #MedEd

📣 Breast cancer data update from #ESMO24 📣 Prof. François-Clément Bidard joined us in Barcelona at the ESMO 2024 congress to share his perspective on the latest breast cancer data. How does he think these data will impact clinical practice? Watch his video update to find out 📺👇 Prof. François-Clément Bidard refers to the following trials: ➡️ Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study. Schmid P, et al. (Abstract LBA4) ➡️ Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINYBreast-12 primary results. Lin N, et al. (Abstract LBA18) ➡️ Adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with HR+/HER2− early breast cancer: 4-year outcomes from the NATALEE trial. Fasching P, et al. (Abstract LBA13) #MedicalEducation #oncology

🚨DESTINYBreast-12 results presented at #ESMO2024 T-Dxd shows promising results for pts with HER2+ mBC, irrespective of active brain metastasis (BM) 12 mo PFS: 61.6% overall (stable BM: 62.9%; active BM: 59.6%) CNS ORR: 71.7% overall (stable BM: 79.2%; active BM: 62.3%) 12 mo OS: 90.3% (pts with BM) 90.6% (pts without BM) Stay tuned for more! #MedEd #ESMO2024

🔍 How can CESM (Contrast-Enhanced Spectral Mammography) improve breast cancer diagnosis? A recent meta-analysis of 12 studies evaluates CESM (Contrast-Enhanced Spectral Mammography) for breast cancer diagnosis. The results are promising: CESM demonstrates high sensitivity (0.97) and good specificity (0.76). Key metrics include a positive likelihood ratio of 4.03, a negative likelihood ratio of 0.05, and a diagnostic odds ratio of 89.49, with an impressive area under the curve (AUC) of 0.95. These findings support CESM’s effectiveness, particularly for women with dense breast tissue. https://ow.ly/aYno50Tgfcp #bcsm #MedEd

ESMO 2024 is fast approaching! In just 8 days, groundbreaking data in the breast cancer field will be unveiled. With numerous impactful presentations on the horizon, which trials should you prioritize? Dr. Paolo Tarantino has spotlighted the top 10 abstracts that warrant special attention—be sure to check them out! Will you be attending ESMO this year?

🧬 Did you know that approximately 50% of our microbiota resides in the gut and plays a crucial role in maintaining our overall homeostasis? A disruption in this balance, known as dysbiosis, is linked to various inflammation-related diseases, including cancer. 🦠 The gut microbiota significantly influences several metabolic pathways, including immune responses, estrogen regulation, lipid metabolism, and polyphenol processing. Recent research highlights that the composition of faecal microbiota can impact breast cancer prognosis and response to treatment. By modulating gut microbiota, we may enhance treatment efficacy and minimize side effects, opening new avenues for improving breast cancer care. Check out this interesting review here: https://ow.ly/l8sb50T0JOZ #MedEd